Rozanolixizumab not checked

UCB Biopharma SRL · UCB7665

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
5 active
22 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“* Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive pre-specified doses of rozanolixizumab.”In the company’s words, NCT05063162 on ClinicalTrials.gov
Tested for
Ocular Myasthenia Gravis (2 trials), Myasthenia Gravis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), Generalized Myasthenia Gravis
Main trialPhase 4
“The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.”In the company’s words, NCT07246564 on ClinicalTrials.gov
Other names
UCB7665 · RLZ

Other drugs for Ocular Myasthenia Gravis

All 37 drugs for Ocular Myasthenia Gravis

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials22

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 15 Oct 2027 Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Phase 3Active, not recruiting 6 May 2027 A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
Phase 3Active, not recruiting 5 Oct 2027 An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
Phase 3Recruiting 1 Dec 2028 A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Phase 3Recruiting 17 Mar 2031 A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Phase 3Completed 31 Aug 2021 A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Phase 3Completed 1 Sep 2021 A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Phase 3Terminated 21 Mar 2022 A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Phase 3Terminated 25 Apr 2022 A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Phase 3Terminated 21 Dec 2022 A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Phase 3Completed 25 Jan 2024 A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Phase 3Completed 23 Apr 2024 A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
Phase 2/3Completed 5 Oct 2026 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Phase 2Completed 31 May 2018 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
Phase 2Completed 4 Feb 2019 Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
Phase 2Completed 31 Mar 2021 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Phase 2Completed 10 Nov 2021 A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Phase 2Terminated 8 Mar 2024 A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Phase 2Completed 28 May 2024 A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
Phase 1Completed 28 Apr 2020 A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants
Phase 1Completed 11 Apr 2022 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants
Phase 1Completed 12 May 2025 A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Rozanolixizumab

Following is part of Solo: you see every change to Rozanolixizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in